Century Therapeutics (IPSC) Cash from Operations (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Cash from Operations of 25262000.0 for Q1 2026, up 27.04% year-over-year from 19885554.43 in Q1 2025, and down 56.9% quarter-over-quarter from 16101000.0 in Q4 2025.
Powered by 
Analysis
Century Therapeutics (IPSC) Cash from Operations (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Cash from Operations for 7 consecutive years, with 25262000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 27.04% year-over-year to 25262000.0; the TTM figure through Mar 2026 stood at 94539000.0 (up 17.44% YoY), while the FY2025 annual figure was 103900000.0, up 5.66% from the prior year.
- Cash from Operations slipped to 25262000.0 in Q1 2026 per IPSC's latest filing, from 16101000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 86753000.0 in Q1 2022 and bottomed at 34623000.0 in Q1 2025.
- Historically, Cash from Operations has averaged 18446647.06 across 5 years, with a median of 25556000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Operations surged 491.15% — and 2023, when it sank 133.68%.
- Century Therapeutics' Cash from Operations stood at 22907000.0 in 2022, then declined by 14.51% to 26230000.0 in 2023, then climbed by 7.65% to 24223000.0 in 2024, then soared by 33.53% to 16101000.0 in 2025, then sank by 56.9% to 25262000.0 in 2026.
- Business Quant data shows IPSC's Cash from Operations at 25262000.0 in Q1 2026, 16101000.0 in Q4 2025, and 25584000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Century Therapeutics | 440.37 Mn | 180.29 Mn | - | -19.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19.83 Mn |
| Mar 31, 2026 | -25.26 Mn |
| Dec 31, 2025 | -16.10 Mn |
| Sep 30, 2025 | -25.58 Mn |
| Jun 30, 2025 | -27.59 Mn |
| Mar 31, 2025 | -34.62 Mn |
| Dec 31, 2024 | -24.22 Mn |
| Sep 30, 2024 | -28.33 Mn |
| Jun 30, 2024 | -27.33 Mn |
| Mar 31, 2024 | -30.25 Mn |
| Dec 31, 2023 | -26.23 Mn |
| Sep 30, 2023 | -13.65 Mn |
| Jun 30, 2023 | -19.25 Mn |
| Mar 31, 2023 | -29.22 Mn |
| Dec 31, 2022 | -22.91 Mn |
| Sep 30, 2022 | -24.24 Mn |
| Jun 30, 2022 | -25.56 Mn |
| Mar 31, 2022 | 86.75 Mn |
| Dec 31, 2021 | -24.35 Mn |
| Sep 30, 2021 | -23.98 Mn |